Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
843.60
+5.40 (+0.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
41
42
Next >
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest
April 25, 2022
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 6.48% since its last report. The company recently reported that it has 2.39 million shares sold...
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
April 12, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:
Via
Benzinga
If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today
April 21, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron...
Via
Benzinga
54 Biggest Movers From Yesterday
April 20, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...
Via
Benzinga
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
April 19, 2022
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it.
Via
InvestorPlace
38 Stocks Moving In Tuesday's Mid-Day Session
April 19, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $...
Via
Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
April 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
April 19, 2022
Via
Benzinga
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
April 19, 2022
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to...
Via
Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
April 17, 2022
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...
Via
Benzinga
NASDAQ: REGN Shareholder Notice: Investigation over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc.
April 15, 2022
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- Regeneron Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
April 14, 2022
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
April 14, 2022
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
Healthcare Stocks Lead the Way Up as the Market Fades
April 11, 2022
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Via
Talk Markets
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Michael Grimm Purchases $5.66 Million Worth Of Energy Transfer & Other Notable Insider Buys
April 11, 2022
Natural gas prices were range bound for the better part of the last decade, oscillating between $2 and $4 per million British thermal units (MMBtu) with the occasional spike...
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
April 09, 2022
Raytheon and Shell are just below buy points. They have good company.
Via
Investor's Business Daily
Is It Time To Tweak Your Investments For An Inflationary Environment?
April 08, 2022
Is it time to tweak your investing portfolio to adapt to the potential for long-term inflation? Here are ways to do so.
Via
Investor's Business Daily
This Is What Whales Are Betting On Regeneron Pharmaceuticals
April 08, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange...
Via
Benzinga
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
April 07, 2022
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.
Via
Investor's Business Daily
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
April 07, 2022
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.
Via
Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
April 07, 2022
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...
Via
Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals Inc?
April 07, 2022
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 4.85% since its last report. The company recently reported that it has 2.24 million shares sold...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
April 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Europe Approves Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6-11 Years With Type 2 Inflammation
April 07, 2022
The
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.